Management

Roger D. Tung, Ph.D. is our scientific founder and has served as our President and Chief Executive Officer and as a member of our board of directors since April 2006. Before Concert, Dr. Tung was a founding scientist at Vertex, a pharmaceutical company, where he was employed from 1989 to 2005, most recently as its Vice President of Drug Discovery. Prior to Vertex, he held various positions at Merck, Sharp & Dohme Research Laboratories, a global healthcare provider, and The Squibb Institute for Medicinal Chemistry. During his career, Dr. Tung has overseen the discovery of five drugs approved for the treatment of HIV, hepatitis C, and cystic fibrosis and was an inventor of several of them. He also serves as a member of the University of Wisconsin-Madison School of Pharmacy’s Board of Visitors, faculty mentor in the MIT IMPACT program, and strategic advisor to Longwood Founder’s Fund. Dr. Tung received a B.A. in Chemistry from Reed College and a Ph.D. in Medicinal Chemistry at the University of Wisconsin-Madison.

Mr. Marc Becker has served as our Chief Financial Officer since January 2018. Prior to joining Concert, Mr. Becker served as Senior Vice President and Chief Financial Officer at CRISPR Therapeutics from February 2016 to September 2017. Prior to joining CRISPR Therapeutics, Mr. Becker served as Chief Financial Officer and Senior Vice President of rEVO Biologics, a biopharmaceutical company, from January 2012 to February 2016. Before rEVO, Mr. Becker spent 10 years at Genzyme Corporation, most recently serving as Finance Director for the UK and Ireland before returning to the United States to become the Vice President of Finance for Genzyme’s Renal and Endocrine business. He also serves on the Board of Directors of Food for Free, a non-profit organization in Cambridge, MA. Mr. Becker began his career in auditing and commercial lending for financial services firms, KPMG and BankBoston. Mr. Becker holds a BS from the University of Massachusetts, an MBA from Babson College and was licensed as a CPA.

Dr. James V. Cassella has served as our Chief Development Officer since February 2015. Prior to joining Concert, Dr. Cassella had senior level roles in biopharmaceutical companies, including Executive Vice President, Research and Development and Chief Scientific Officer of Alexza Pharmaceuticals, Inc. from June 2004 to January 2015. Prior to Alexza Pharmaceuticals, Dr. Cassella held various management positions at Neurogen Corporation, including Senior Vice President, Clinical Research and Development. Before joining the biotechnology industry, Dr. Cassella was Assistant Professor of Neuroscience at Oberlin College. He also serves on the Board of Directors of Trevi Therapeutics, Inc. Dr. Cassella received his Ph.D. in Physiological Psychology from Dartmouth College, completed a postdoctoral fellowship in the Department of Psychiatry at the Yale University School of Medicine and received a B.A. in psychology from the University of New Haven.

Mr. Jeffrey A. Munsie has served as our Chief Legal Officer since September 2019. Prior to joining Concert Mr. Munsie served as Senior Vice President, General Counsel and Head of Corporate Operations at Merrimack Pharmaceuticals, a biopharmaceutical company, from 2011 to 2019. Prior to Merrimack, he was a member of the corporate department at the law firm Wilmer Cutler Pickering Hale and Dorr in Boston from 2002 to 2011. Mr. Munsie received a J.D. from Harvard Law School and a B.A. from Dartmouth College.

Ms. Nancy Stuart has served as our Chief Operating Officer since October 2007 and was our Senior Vice President, Corporate Strategy and Operations from July 2006 to October 2007. Prior to joining Concert Ms. Stuart held various business operations and business development positions at Amgen Inc., a biopharmaceutical company, Kinetix Pharmaceuticals, Inc., a pharmaceutical company subsequently acquired by Amgen, Vertex, a pharmaceutical company and Genzyme Corporation, a biotechnology company subsequently acquired by Sanofi S.A. She also serves on the Board of Directors of KalVista Pharmaceuticals, a pharmaceutical company, and The Greater Boston YMCA. Ms. Stuart holds a B.S. from the University of Michigan, and an M.B.A. from the Simmons College Graduate School of Management.

Ms. Christine Boisclair joined Concert in June 2016 and currently serves as Senior Vice President, Regulatory Affairs and Quality Assurance. She has with more than 30 years Regulatory Affairs experience in the biopharmaceutical industry and across multiple therapeutic areas. Prior to joining Concert, Ms. Boisclair was Vice President, Regulatory Affairs at Forum Pharmaceuticals. Before joining Forum Pharmaceuticals Ms. Boisclair held management roles at several companies including Insmed Inc, Agennix Inc, OSI Pharmaceuticals Inc, Genzyme Corporation, Immulogic Pharmaceuticals and Parexel International. Ms. Boisclair began her regulatory career at Searle Pharmaceuticals and Glaxo in the UK.She received a Bachelor of Science Honors Degree in Biochemistry from the University of York in the United Kingdom.

Ms. Justine Koenigsberg joined Concert in March 2008 and currently serves as Senior Vice President, Corporate Communications and Investor Relations. She has more than 25 years corporate communications and investor relations experience within the biotechnology industry. Prior to joining Concert she held senior communication roles at ViaCell, Inc. and Transkaryotic Therapies (TKT) where she developed and implemented a variety of communication strategies and managed their investor relations programs. Prior to TKT, she held communications positions at Vertex Pharmaceuticals. Ms. Koenigsberg is a member of the National Investors Relations Institute and served on the Board of Directors and as a Past-President of its Boston Chapter. She holds a B.S. in Business Administration from Northeastern University.

Dr. Christopher L. Brummel joined Concert in March 2015 and currently serves as Vice President, Drug Metabolism and Pharmacokinetics (DMPK) and Bioanalysis (BA). He has more than 24 years of experience in the pharmaceutical and biotechnology industry in the fields of DMPK, BA and Analytical Chemistry. Prior to joining Concert, Dr. Brummel worked at Vertex Pharmaceuticals and Celgene in DMPK and BA and Analytical Chemistry. He earned his Baccalaureate in Chemistry with Honors as a Carleton B Edwards scholar from Earlham College, a Ph.D. in Physical Chemistry and Biophysical Chemistry from Cornell University as an NIH predoctoral fellow, and was a postdoctoral fellow at The Pennsylvania State University.

Dr. Cameron Cowden joined Concert in January 2016 and currently serves as Vice President, Pharmaceutical Development. He has nearly 20 years of process chemistry and chemical engineering experience in the pharmaceutical industry. Prior to joining Concert, Dr. Cowden was an Executive Director in Process Chemistry at Merck. He received his Ph.D. from the University of Melbourne, Australia and was a postdoctoral fellow at Cambridge University in the United Kingdom.

Mr. K. Mitch Goldenberg joined Concert in 2008 and currently serves as Vice President, IT and Infrastructure. He has over 25 years of experience in information technology and operations. Prior to joining Concert, Mr. Goldenberg worked for H&R Block and PTC. He received a B.S. in Computer and Systems Engineering from Rensselaer Polytechnic Institute and a masters degree from Harvard Extension School in Information Management Systems.

Ms. Kimberly Mack joined Concert in October 2006 and currently serves as Vice President, Human Resources. She has more than 25 years human resources experience within the biotechnology industry. Prior to joining Concert, Kimberly held senior human resources roles at Wyeth Pharmaceuticals, Cubist Pharmaceuticals and ArQule.  She holds a B.S. in Business Administration from Bentley University.

Mr. Daniel Morse joined Concert in January 2016 and currently serves as Vice President, Global Supply Chain. He has over 25 years of supply chain experience in the pharmaceutical industry. Prior to joining Concert, Mr. Morse was Head of Clinical Supply Chain at Ariad Pharmaceuticals. Before joining Ariad, Mr. Morse held supply chain management roles at several companies including AVEO, Vertex Pharmaceuticals, Wyeth BioPharma and Genetics Institute. Mr. Morse began his career at Immulogic Pharmaceuticals. He received a B.S. in Biology from Northeastern University.

Dr. Nabil Uddin joined Concert in 2014 and currently serves as Vice President, Corporate Development. He has over 15 years of experience in the biotech industry encompassing program and portfolio management and business development roles with a particular emphasis on CNS disorders and rare diseases. Prior to joining Concert, Dr. Uddin worked at Seaside Therapeutics, a company focused on neurodevelopmental disorders such Fragile X Syndrome and autism spectrum disorders. He earned a BSc. in Biology from McMaster University, a Pharm.D. from the Massachusetts College of Pharmacy and completed a post-doctoral fellowship at the University of North Carolina at Chapel Hill.